RhumbLine Advisers
DMAC icon

RhumbLine Advisers’s DiaMedica Therapeutics DMAC Stock Holding History

RhumbLine Advisers’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$221K Buy
31,460
+8,707
+38% +$53.5K ﹤0.01% 3232
2026
Q1 		$154K Sell
22,753
-4,008
-15% -$31.8K ﹤0.01% 3238
2025
Q4 		$213K Sell
26,761
-596
-2% -$4.46K ﹤0.01% 3155
2025
Q3 		$188K Buy
27,357
+3,463
+14% +$18.8K ﹤0.01% 3252
2025
Q2 		$93.2K Buy
+23,894
New +$93.2K ﹤0.01% 3553

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RhumbLine Advisers's DMAC Position: Q2 2026 in Review

RhumbLine Advisers increased its DiaMedica Therapeutics (DMAC) stake by 38% in Q2 2026, buying an estimated $53.5K and bringing the position to 31,460 shares worth $221K. The position accounts for ﹤0.01% of the portfolio, ranked #3232.

RhumbLine Advisers first reported a position in DMAC in Q2 2025 and has held it in 5 quarters since. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • RhumbLine Advisers held 31,460 shares of DiaMedica Therapeutics worth $221K as of Q2 2026.
  • RhumbLine Advisers bought 8,707 DiaMedica Therapeutics shares in Q2 2026, an estimated $53.5K.
  • DiaMedica Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3232 holding.
  • RhumbLine Advisers first reported a position in DiaMedica Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.